Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Gene-Targeting drug could change how we treat high blood pressure

NCT ID NCT06205628

Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 4 times

Summary

This early-stage study tests a new drug called ADX-850 in 28 people with mild to moderate high blood pressure. The drug uses siRNA technology to target genes involved in blood pressure regulation. The main goal is to check safety and how the drug moves through the body, with a secondary look at its effect on blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ADX-850 (siRNA drug)
What this could lead to
If successful, this could lead to a new treatment option for high blood pressure that may require less frequent dosing.
What could go wrong
This is an early Phase 1 study with only 28 participants, so safety and effectiveness are not yet proven. The drug may not lower blood pressure enough or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

28 people

The number who actually took part.

Started

Mar 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Body mass index (BMI) between 18 and 35 kg/m2 * Mild to moderate hypertension, mean of \>130 and \<165mmHg * No use of antihypertensive medication for a minimum of 2 weeks * Willing and able to comply with all study requirements * Willing to take irbesartan as concomitant ARB therapy (Part 2 only) * Must be a non-smoker for the duration of the study Key Exclusion Criteria: * Secondary hypertension * Active malignancy and/or history of malignancy in the past 5 years * History of liver disease, Gilbert's syndrome, nonalcoholic steatohepatitis, severe steatosis, or abnormal liver function test results * Any active infection or acute illness * Major surgery or significant traumatic injury occurring within 3 months * Mean sitting diastolic BP (DBP) ≥110 mmHg * Orthostatic hypotension * Significant kidney disease or eGFR \<60 mL/min/1.73m2 * Abnormal potassium levels * History or presence of clinically significant ECG abnormalities * Treatment with another investigational product within 30 days prior to the first study drug administration * Pregnant, intend to become pregnant during the course of the study, or lactating * History of alcohol abuse * Night shift workers (regular working hours between 10:00 PM and 6:00 AM) * Any other significant medical history, such as major cardiovascular events or cancer * Known history of intolerance to ARB medication (Part 2 only)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension essential hypertension, genetic hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Hypertension,essential

Contacts and locations

Locations

  • CMAX Clinical Research

    Adelaide, South Australia, 5000, Australia

  • Clinitrials Pty Ltd

    Perth, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.